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The authors note that due to a printer error, **[Figure 3b](#fig1){ref-type="fig"}** appears incorrectly in part. The Y-axis label should instead appear as "Pravastatin plasma conc. (µmol/l)." The corrected figure and its legend appear below.

![Validation of physiology-based pharmacokinetic (PBPK) models for simvastatin acid and pravastatin at the organism level and at the molecular scale. (**a**,**b**) Model-based prediction of pharmacokinetic phenotypes. After adjustment of model parameters with respect to the homozygous genotype TT (black; experiment: triangle (up)), the minor frequent homozygous genotype (CC, light gray; experiment: triangle (down)) was simulated by decreasing the transporter activity for (**a**) simvastatin acid^28^ and (**b**) pravastatin^27^ (all simulations are indicated by a solid line). Taking the average of the transporter activity of both homozygous genotypes correctly predicts the plasma curves of the heterozygous genotype (TC, dark gray; triangle diamonds) for both drugs. (**c**) Model-based prediction of the effect of the solute carrier organic anion transporter family member 1B1 single-nucleotide polymorphism on the transporter activities at the molecular scale. The ratio of transporter activities is different for simvastatin acid (black) and pravastatin (white). This PBPK model-based finding (left) could be verified with *in vitro* assays (right) using HEK 293 cells and \[^3^H\]-labeled pravastatin and simvastatin acid. \**P* \< 1 × 10^−4^, randomization test.](psp201222f1){#fig1}
